is there a patent on semaglutide Ozempic's problem: how Novo Nordisk lost control of blockbuster drug. 💉 Demand for GLP-1 weight-loss drugs has exploded, turning Ozempic into a $40bn+ revenue engine for Novo Nordisk. But, despite India Obesity Crisis: The Expiry

These are signs that the glucagon component is driving energy expenditure at a level that meaningfully contributes to the overall weight loss beyond what GLP-1 and GIP provide alone

More significant lightening requires eight or more sessions delivered weekly or bi-weekly

Furthermore, although clinicopathological characteristics are summarized in Additional File 1, residual confounding by clinical or pathological factors cannot be completely excluded

Seino, Y., Min, K

The results confirmed the benefit-risk profile of currently approved doses of semaglutide for clinically meaningful glucose and weight management in people with T2D